| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 2044 from our risk checks.
Meinian Onehealth Healthcare Holdings Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.81 |
| 52 Week High | CN¥7.42 |
| 52 Week Low | CN¥4.43 |
| Beta | 0.74 |
| 1 Month Change | -3.41% |
| 3 Month Change | -3.41% |
| 1 Year Change | -31.38% |
| 3 Year Change | -60.89% |
| 5 Year Change | -62.30% |
| Change since IPO | -64.38% |
Recent News & Updates
Shareholder Returns
| 2044 | CN Healthcare | CN Market | |
|---|---|---|---|
| 7D | 5.3% | 0.2% | -0.3% |
| 1Y | -31.4% | -35.2% | -14.6% |
Return vs Industry: 002044 exceeded the CN Healthcare industry which returned -35.2% over the past year.
Return vs Market: 002044 underperformed the CN Market which returned -14.6% over the past year.
Price Volatility
| 2044 volatility | |
|---|---|
| 2044 Average Weekly Movement | 5.2% |
| Healthcare Industry Average Movement | 6.7% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 002044 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002044's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 38,147 | Tao Xu | www.health-100.cn |
Meinian Onehealth Healthcare Holdings Co., Ltd. engages in the health examination business. It integrates health consultation, health assessment, and health intervention services.
Meinian Onehealth Healthcare Holdings Co., Ltd. Fundamentals Summary
| 2044 fundamental statistics | |
|---|---|
| Market cap | CN¥17.82b |
| Earnings (TTM) | CN¥505.62m |
| Revenue (TTM) | CN¥10.89b |
37.0x
P/E Ratio1.7x
P/S RatioIs 2044 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2044 income statement (TTM) | |
|---|---|
| Revenue | CN¥10.89b |
| Cost of Revenue | CN¥6.23b |
| Gross Profit | CN¥4.66b |
| Other Expenses | CN¥4.16b |
| Earnings | CN¥505.62m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 42.79% |
| Net Profit Margin | 4.64% |
| Debt/Equity Ratio | 28.0% |
How did 2044 perform over the long term?
See historical performance and comparison